ARTICLE SUMMARY:
In a little over a year, five PMA approvals and two financing events point to robust growth in the market for minimally invasive obesity devices.
Obalon Therapeutics Inc. priced its IPO last week; it intends to offer five million shares in the range of $14-16 per share, which will give it a market cap of approximately $250 million.
